Independent Research Reiterates €100.00 Price Target for Merck KGaA (MRK)

Merck KGaA (FRA:MRK) has been given a €100.00 ($116.28) price objective by research analysts at Independent Research in a report issued on Thursday. The firm presently has a “neutral” rating on the healthcare company’s stock. Independent Research’s price objective suggests a potential upside of 4.67% from the stock’s previous close.

Several other research firms have also issued reports on MRK. Deutsche Bank set a €93.00 ($108.14) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, October 30th. Berenberg Bank set a €104.00 ($120.93) price target on shares of Merck KGaA and gave the stock a “buy” rating in a report on Thursday, August 9th. Goldman Sachs Group set a €92.00 ($106.98) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Monday, September 24th. Nord/LB set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Thursday, August 9th. Finally, Kepler Capital Markets set a €105.00 ($122.09) price target on shares of Merck KGaA and gave the stock a “buy” rating in a report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have assigned a buy rating to the company. Merck KGaA has an average rating of “Hold” and an average target price of €98.00 ($113.95).

FRA MRK traded up €2.04 ($2.37) on Thursday, hitting €95.54 ($111.09). The stock had a trading volume of 607,494 shares. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: Short Selling Stocks and Day Traders

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply